Daishi Tian
Clinical trials sponsored by Daishi Tian, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could CAR-T cells tame multiple sclerosis? early trial launches Results expected Jan 2027 (estimated)
- Experimental CAR-T therapy takes aim at Tough-to-Treat myasthenia gravis Results expected Feb 2027 (estimated)
- Experimental STAR-T cell therapy aims to tame multiple sclerosis Results expected Apr 2027 (estimated)
- Engineered immune cells take aim at debilitating muscle weakness Results expected Jul 2027 (estimated)
- CAR-T cells take on stubborn muscle disease in first human test Results expected Sep 2027 (estimated)
-
Can a single injection tame stubborn multiple sclerosis?
Disease control Not yet recruitingThis early-stage trial is testing an investigational injection called GT802 in people with relapsing or refractory multiple sclerosis (MS) — meaning their disease is active despite standard treatments. The study aims to check whether GT802 is safe and to get a first look at wheth…
Early phase 1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Engineered immune cells take aim at debilitating muscle weakness
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal STAR-T cells—engineered immune cells—in adults aged 18 to 65 with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. The study aims to assess safety, tolerability, and signs of effectiv…
Phase 1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental STAR-T cell therapy aims to tame multiple sclerosis
Disease control Not yet recruitingThis early-stage trial will test the safety of a new immune cell therapy called universal STAR-T cells in 24 adults with multiple sclerosis (MS) who have no other treatment options. The therapy involves infusing specially engineered cells that may help control the disease. The st…
Phase 1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC